Author | Ruth M. O'Regan, MD | OncLive

Author | Ruth M. O'Regan, MD

Articles

Dr. O'Regan Discusses the Future of Treatment in HER2+ Breast Cancer

May 16, 2017

Video

Ruth O’Regan, MD, division head of Hematology and Oncology in the Department of Medicine at the University of Wisconsin School of Medicine and Public Health, discusses the potential of future treatments for patients with HER2-positive breast cancer.

Dr. O'Regan Discusses BELLE-3 Study in Breast Cancer

January 07, 2017

Video

Ruth O’Regan, MD, division head of Hematology and Oncology in the Department of Medicine at the University of Wisconsin School of Medicine and Public Health, discusses BELLE-3, a phase III study of buparlisib (BKM120) plus fulvestrant (Faslodex) in postmenopausal women with hormone receptor (HR)-positive, HER2-negative, locally advanced or metastatic breast cancer, who progressed on or after mTOR inhibitor-based treatment and were treated with an aromatase inhibitor.

Dr. O'Regan Discusses Breast Cancer Index in HER2-Positive/HR-Positive Patients

June 17, 2015

Video

Ruth O'Regan, MD, medical oncology, Breast Cancer Clinic, University of Wisconsin Carbone Cancer Center, faculty, University of Wisconsin School of Medicine and Public Health, evaluates the Breast Cancer Index in patients with HER2-positive, HR-positive breast cancer for risk of late recurrence and endocrine benefit.

Dr. O'Regan Discusses Updates in HER2-Positive Breast Cancer

August 14, 2014

Video

Ruth M. O'Regan, MD, director, Translational Breast Cancer Research, professor, hematology and oncology, medical oncology, Winship Cancer Institute, Emory University, discusses updates in the field of adjuvant therapy for HER2-positive breast cancer.

x